The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment

BACKGROUND: Renal impairment is a common feature in multiple myeloma and is considered a poor prognostic factor. AIM: To determine the impact of novel drugs (i.e. bortezomib, lenalidomide and thalidomide) in the treatment of myeloma patients with renal impairment. The primary endpoint was overall su...

Descripción completa

Detalles Bibliográficos
Autores principales: Uttervall, Katarina, Duru, Adil D., Lund, Johan, Liwing, Johan, Gahrton, Gösta, Holmberg, Erik, Aschan, Johan, Alici, Evren, Nahi, Hareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086950/
https://www.ncbi.nlm.nih.gov/pubmed/25003848
http://dx.doi.org/10.1371/journal.pone.0101819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086950/
https://www.ncbi.nlm.nih.gov/pubmed/25003848
http://dx.doi.org/10.1371/journal.pone.0101819

Ejemplares similares